VIVS · VivoSim Labs, INC. · Insider Trading

The reported securities are represented by restricted stock units, which shall vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.

The reported securities are represented by restricted stock units, which shall vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.

Effective on March 20, 2025, the Issuer conducted a reverse stock split of its common stock at a ratio of 1-for-12 (the "Reverse Split"). All share numbers reported herein give effect to the Reverse Split.

The reported securities are represented by restricted stock units, which shall vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.

Effective on March 20, 2025, the Issuer conducted a reverse stock split of its common stock at a ratio of 1-for-12 (the "Reverse Split"). All share numbers reported herein give effect to the Reverse Split.

The reported securities are represented by restricted stock units, which shall vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.

Effective on March 20, 2025, the Issuer conducted a reverse stock split of its common stock at a ratio of 1-for-12 (the "Reverse Split"). All share numbers reported herein give effect to the Reverse Split.

The reported securities are represented by restricted stock units, which shall vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.

Effective on March 20, 2025, the Issuer conducted a reverse stock split of its common stock at a ratio of 1-for-12 (the "Reverse Split"). All share numbers reported herein give effect to the Reverse Split.

The option vests over a four year period, with 25% of the total number of shares subject to the option vesting on November 24, 2026, and the balance vesting in 12 equal quarterly installments thereafter.

Effective on March 20, 2025, the Issuer conducted a reverse stock split of its common stock at a ratio of 1-for-12 (the "Reverse Split"). All share numbers reported herein give effect to the Reverse Split.

The option vests over a four year period, with 25% of the total number of shares subject to the option vesting on the August 11, 2026, and the balance vesting in 12 equal quarterly installments thereafter.

The reported securities are represented by restricted stock units, which shall vest on the earlier of August 7, 2025 or the date of the next annual meeting of stockholders held by the Issuer in 2025, subject to acceleration in the event of a change of control.

The reported securities are represented by restricted stock units, which shall vest on the earlier of August 7, 2025 or the date of the annual meeting of stockholders held by the Issuer in 2025, subject to acceleration in the event of a change of control.

The reported securities are represented by restricted stock units, which shall vest on the earlier of August 7, 2025 or the date of the next annual meeting of stockholders held by the Issuer in 2025, subject to acceleration in the event of a change of control.

The reported securities are represented by restricted stock units, which shall vest on the earlier of August 7, 2025 or the date of the next annual meeting of stockholders held by the Issuer in 2025, subject to acceleration in the event of a change of control.

The reported securities are represented by restricted stock units, which shall vest on the earlier of August 7, 2025 or the date of the next annual meeting of stockholders held by the Issuer in 2025, subject to acceleration in the event of a change of control.

The reported securities are represented by restricted stock units, which shall vest on the earlier of August 7, 2025 or the date of the next annual meeting of stockholders held by the Issuer in 2025, subject to acceleration in the event of a change of control.

The option vests in 3 equal annual installments on each of August 5, 2025, August 5, 2026 and August 5, 2027.

The option becomes exercisable if, after the grant date, the closing sales price of the Common Stock, as reported on the Nasdaq Capital Market (based on a 90-trading day average), is at least $1.53 (subject to adjustment for stock splits), as confirmed by the Board of Directors or a committee thereof.

The reported securities are represented by restricted stock units, which shall vest on the earlier of November 17, 2024 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.

The reported securities are represented by restricted stock units, which shall vest on the earlier of November 17, 2024 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.

The reported securities are represented by restricted stock units, which shall vest on the earlier of November 17, 2024 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.

The reported securities are represented by restricted stock units, which shall vest on the earlier of November 17, 2024 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.

The reported securities are represented by restricted stock units, which shall vest on the earlier of November 17, 2024 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.

The reported securities are represented by restricted stock units, which shall vest on the earlier of November 17, 2024 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.615 to $1.64, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.

The reported securities are represented by restricted stock units, which shall vest on the earlier of November 9, 2023 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.

The reported securities are represented by restricted stock units, which shall vest on the earlier of November 9, 2023 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.

The reported securities are represented by restricted stock units, which shall vest on the earlier of November 9, 2023 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.

The reported securities are represented by restricted stock units, which shall vest on the earlier of November 9, 2023 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.

The reported securities are represented by restricted stock units, which shall vest on the earlier of November 9, 2023 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.

The reported securities are represented by restricted stock units, which shall vest on the earlier of November 9, 2023 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.

The option shares will vest on a quarterly basis over a period of forty-eight (48) months from August 31, 2022.

The option shares will vest on a quarterly basis over a period of forty-eight (48) months from August 31, 2022.

The option shares will vest on a quarterly basis over a period of forty-eight (48) months from August 31, 2022.

The option shares vest and become exercisable over twelve equal quarterly installments measured from March 8, 2022.

The Reporting Person previously reported holding 2,600 shares of the Issuer's common stock, but this was adjusted to 130 shares of the Issuer's common stock to reflect the 1-for-20 reverse stock split of the Issuer's common stock that occurred on August 18, 2020. The number previously reported also inadvertently underreported 300 shares held by the Reporting Person (15 shares after giving effect to the aforementioned 1-for-20 reverse stock split).

The option shares shall vest and become exercisable on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.

The option becomes exercisable, if at all, if the 45-day moving average closing price of the Issuer's common stock on The Nasdaq Stock Market LLC exceeds $30.00 per share.

The option shares shall vest and become exercisable on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.

The option becomes exercisable, if at all, if the 45-day moving average closing price of the Issuer's common stock on The Nasdaq Stock Market LLC exceeds $35.00 per share.

The option shares shall vest and become exercisable on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.

1/16th of the option shares shall vest and become exercisable on January 7, 2022 and on each three-month anniversary thereafter.

The option shares shall vest and become exercisable on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.

1/16th of the option shares shall vest and become exercisable on January 7, 2022 and on each three-month anniversary thereafter.

The option becomes exercisable, if at all, if the 45-day moving average closing price of the Issuer's common stock on The Nasdaq Stock Market LLC exceeds $30.00 per share.

The option becomes exercisable, if at all, if the 45-day moving average closing price of the Issuer's common stock on The Nasdaq Stock Market LLC exceeds $35.00 per share.

The option shares shall vest and become exercisable on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.725 to $6.74, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.705 to $6.74, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.

The Reporting Person previously reported holding 25,000 shares of the Issuer's common stock, but this was adjusted to 1,250 shares of the Issuer's common stock to reflect the 1-for-20 reverse stock split that occurred on August 18, 2020.

25% of the option shares vest and become exercisable on December 31, 2021 and the remaining shares vest in 12 equal quarterly installments thereafter.